Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Exelixis, Inc. (EXEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed oncology-focused biopharmaceutical company, Exelixis uses these filings to report material events, financial results, capital allocation decisions and changes in senior leadership.
Form 8-K filings for EXEL include items such as quarterly financial results and corporate updates, stock repurchase program authorizations and executive appointments or departures. For example, Exelixis has filed 8-Ks describing the authorization of a stock repurchase program for up to a specified amount of common stock before a stated date, as well as the appointment of an Executive Vice President, Research and Development and the planned transition of its General Counsel role. These filings complement the company’s earnings press releases by providing structured information on results of operations and significant corporate actions.
Investors and analysts can use Exelixis’ SEC filings to track how the company reports revenue from its cabozantinib franchise, outlines research and development and selling, general and administrative expenses, and communicates guidance ranges for future periods. While detailed financial statements and management discussion are found in periodic reports such as Forms 10-K and 10-Q, current reports on Form 8-K highlight timely developments that may affect the company’s outlook or governance.
On Stock Titan, EXEL filings are accompanied by AI-powered summaries designed to clarify the key points in complex documents. These summaries help readers quickly understand the implications of new filings, from capital return plans to leadership changes, while links to the full text allow for deeper review. The filings page also serves as a starting point for researching topics such as repurchase authorizations, executive transitions and other events that Exelixis has deemed material enough to disclose under SEC rules.
Exelixis, Inc. director filed a Form 4 reporting the sale of 100,000 shares of common stock on 11/12/2025 at a $43.55 weighted average price, with sales executed between $43.55 and $43.58.
After the transaction, the reporting person beneficially owned 1,189,228 shares directly. This amount includes 9,812 RSUs, each representing the right to receive one share upon vesting.
Exelixis (EXEL) President and CEO Michael M. Morrissey filed a Form 4 reporting charitable and estate-planning stock transfers. On 11/11/2025, he gifted 160,000 shares of common stock to the Bombora Rise Foundation. On 11/12/2025, he gifted 101,548 shares to the Morrissey Family Living Trust and 80,000 shares to a donor advised fund. All gifts were at a reported price of $0 per share (transaction code G).
Following these transactions, the filing shows 1,714,404 shares held by the Morrissey Family Living Trust and 17,728 shares held via the Exelixis 401(k) Plan. It also notes 1,416,692 shares that will be issued upon vesting of RSUs and PSUs, each representing one share of common stock.
Exelixis, Inc. executive reports stock sale and updated holdings. The EVP of Research and Development sold 48,383 shares of Exelixis common stock on 11/11/2025 at a weighted average price of $42.50 per share, in multiple trades between $42.50 and $42.58. After this transaction, the executive beneficially owns 664,778 shares, including 431,306 shares that will be issued upon vesting of restricted stock units and 5,835 shares held through the Exelixis 401(k) Plan as of November 10, 2025. The filing is made by a single reporting person in the capacity of officer.
Exelixis (EXEL) director reported insider activity on 11/11/2025. The reporting person exercised 5,784 options at $23.24 per share, then sold 5,784 shares at $42.03 and 18,838 shares at a $41.9 weighted average (sales ranged from $41.81 to $42.02).
Following these transactions, the filing shows 21,380 shares beneficially owned, which footnote (1) states includes shares to be issued upon vesting of RSUs. The option exercised was part of a grant that became fully exercisable on January 5, 2024 and expires January 4, 2031. After the reported transactions, 16,710 derivative securities (options) remain beneficially owned.
Exelixis (EXEL) announced a leadership transition in its legal team. Executive Vice President and General Counsel Jeffrey Hessekiel, J.D., notified the company of his intention to resign effective in November 2025 and will cease serving as General Counsel on November 7, 2025. The company stated his decision was not due to any disagreement.
Brenda Hefti, J.D., Ph.D., currently Senior Vice President, IP & Licensing, will be promoted to General Counsel effective November 7, 2025, reporting to President and CEO Michael Morrissey, Ph.D. Dr. Hefti joined Exelixis in 2013, became Head of IP in 2014, and has served as SVP, IP & Licensing since 2020.
Exelixis reported stronger Q3 results, with total revenues of
For the first nine months, revenues reached
Exelixis (EXEL) reported quarterly results via a press release for the quarter ended October 3, 2025, which was furnished as Exhibit 99.1. The company also provided a corporate update.
The Board authorized a stock repurchase program allowing Exelixis to buy back up to $750 million of its common stock before December 31, 2026. This authorization sets a ceiling and timeframe for potential repurchases.
Exelixis insider equity award and holdings update. An Exelixis executive received 50,673 restricted stock units (RSUs) on
On August 29, 2025, Exelixis, Inc. announced an internal leadership change: Dana T. Aftab, Ph.D., currently the company’s Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, was appointed Executive Vice President, Research and Development. The filing states information about Dr. Aftab’s background, compensation arrangements, and any related-party transactions is incorporated by reference from the company’s definitive proxy statement on Schedule 14A filed April 16, 2025. Effective the same day, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, and is entitled to payments under the company’s Change in Control and Severance Benefit Plan, as amended, and applicable law.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
